Pacific Edge Closes Rights Offer

11 December 2019

PACIFIC EDGE CLOSES RIGHTS OFFER


Pacific Edge Limited (“Pacific Edge”) advises that it has successfully completed its underwritten 1 for 4.25 pro-rata
renounceable rights issue (“Offer”). The Offer was announced on 21 November 2019 and will raise approximately
NZ$20 million.

The shares taken up under the Offer are expected to be allotted and commence trading on 18 December 2019.

The Offer was fully underwritten by Forsyth Barr Group Limited and Jarden Partners Limited (together the
“Underwriters”). In accordance with the terms of the Underwriting Agreement between Pacific Edge and the
Underwriters dated 21 November 2019, the 14.99% under subscription will be taken up in full by the Underwriters
and sub-underwriters.

- ENDS –



For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is
developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central
laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre
clinical studies.

Pacific Edge has four proprietary, non-invasive, accurate, molecular diagnostic products in-market providing actionable results,
and better detection and management of urothelial cancer.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect is commercially available in New Zealand, Australia and the USA as a Laboratory Developed
Test (LDT) from the company’s CLIA certified laboratories. Cxbladder Detect provides clinicians with a quick, cost effective and
accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic
test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient specific clinical factors
to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires life-

long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose
Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is
designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of
recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from
a small quantity of a patient’s urine, with patient characteristics for the identification of patients who are likely to have
aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria
and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying
patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment
options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.